Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $35,692.09 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 1,127 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the transaction, the insider owned 10,914 shares in the company, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Trading Down 3.4%

Teva Pharmaceutical Industries stock opened at $30.46 on Thursday. The stock has a 50-day moving average price of $33.00 and a 200 day moving average price of $26.53. The company has a market capitalization of $35.02 billion, a price-to-earnings ratio of 25.38, a price-to-earnings-growth ratio of 10.55 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TEVA shares. Barclays upped their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of the business. Norges Bank purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $1,098,060,000. Menora Mivtachim Holdings LTD. boosted its stake in shares of Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after purchasing an additional 9,303,978 shares during the last quarter. Soundwatch Capital LLC purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $143,533,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after buying an additional 6,878,304 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.